TUMOR GROWTH AND
GROWTH FRACTION
The rate of growth of human
and experimental cancers is initially quite rapid (exponential) and then slows
un-til a plateau is reached. The decrease in growth rate with increasing tumor
size is related both to a decrease in the proportion of cancer cells actively
proliferating (termed the growth fraction)
and to an increase in the rate of cell loss due to hypoxic necrosis, poor
nutrient supply, im-munological defense mechanisms, and other processes.
The rate of spontaneous cell death
for some human tumors is thought to be a significant factor in limiting growth.
However, the growth fraction, or percentage of cells in the cell cycle, is the
most important determinant of overall tumor enlargement. The doubling times of
human tumors have been estimated by direct measure-ment of chest radiographs of
lesions or palpable masses to be 1 to 6 months.
The growth fraction indicates dividing cells that are potentially
sensitive to chemotherapy; thus, it is not sur-prising that tumors with high
growth fractions are the ones most easily curable by drugs. Among human tumors,
only Burkitt’s lymphoma and trophoblastic choriocarci-noma are readily curable
by single-agent chemotherapy; both of these tumors have growth fractions close
to 100%.
As tumors grow larger, the
growth fraction within the tu-mor decreases, and the greater the distance of
cells from nutrient blood vessels, the more likely they are to be in the G0-,
or resting, phase. The growth fraction is less than 10% for slow-growing cancers
of the colon or lung.
A number of factors must be
considered before chemotherapy is instituted for a human cancer that has a low
growth fraction. For instance, the larger the tumor, the more cells will be
present in the nonproliferating, rel-atively resistant state. Therefore, the
earlier chemother-apy is instituted, the greater the chance of a favorable
re-sponse. Debulking of tumors by surgery or radiation therapy may be a means
of stimulating the remaining cells into active proliferation. Small metastases
may re-spond to drugs more dramatically than will large primary tumors or a
larger metastasis in the same patient.
Several cycles of treatment
may be necessary to achieve a substantial reduction in tumor size. The
chemotherapeutic regimen, especially when one is deal-ing with large, solid
tumors, probably should include agents that have cytotoxic activity against
resting cells.
Related Topics
Privacy Policy, Terms and Conditions, DMCA Policy and Compliant
Copyright © 2018-2024 BrainKart.com; All Rights Reserved. Developed by Therithal info, Chennai.